Skip to main content
Contact Us
Subscribe
E-Edition
82°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Evolus Inc
(NQ:
EOLS
)
16.75
+0.43 (+2.63%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Evolus Inc
< Previous
1
2
3
4
Next >
Evolus to Participate in Stifel 2024 Healthcare Conference
November 01, 2024
From
Evolus
Via
Business Wire
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
October 31, 2024
From
Evolus
Via
Business Wire
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
October 29, 2024
From
Evolus, Inc.
Via
Business Wire
Evolus to Report Third Quarter Financial Results on November 6, 2024
October 23, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 11, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 27, 2024
From
Evolus
Via
Business Wire
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
September 06, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
Evolus
Via
Business Wire
Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
July 31, 2024
From
Evolus
Via
Business Wire
Evolus to Hold Investor Day on September 12, 2024
July 31, 2024
From
Evolus
Via
Business Wire
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia
July 30, 2024
From
Evolus, Inc.
Via
Business Wire
Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
July 25, 2024
From
Evolus
Via
Business Wire
Evolus to Report Second Quarter Financial Results on July 31, 2024
July 17, 2024
From
Evolus
Via
Business Wire
Evolus Announces Appointment of Albert G. White III to Board of Directors
July 01, 2024
From
Evolus
Via
Business Wire
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
June 24, 2024
From
Evolus
Via
Business Wire
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
June 12, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Evolus
Via
Business Wire
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
May 20, 2024
From
Evolus
Via
Business Wire
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
May 15, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
Evolus
Via
Business Wire
Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
May 10, 2024
From
Evolus, Inc.
Via
Business Wire
Evolus Reports First Quarter 2024 Results and Provides Business Update
May 07, 2024
From
Evolus
Via
Business Wire
Evolus to Report First Quarter Financial Results on May 7, 2024
April 23, 2024
From
Evolus
Via
Business Wire
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
April 17, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 12, 2024
From
Evolus
Via
Business Wire
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024
From
Evolus
Via
Business Wire
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
March 11, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
Evolus
Via
Business Wire
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
March 07, 2024
From
Evolus
Via
Business Wire
Evolus Announces Results from European Head-to-Head Filler Trial
March 01, 2024
From
Evolus
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.